Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Cue Biopharma, Inc.

CUE · Nasdaq · CIK 0001645460 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

30 Form 4 transaction lines observed in the same window
15 sales · 15 option, withholding, award, gift or other lines

Last qualifying purchase2025-12-30 · Sarraf Pasha · $99.7K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Lin Shao-LeeChief Executive Officer
○○○▼▼▼
Ray SumitaChief Legal Compliance Officer
○○▼▼
Meluzio Michael VincentVP, Prin. Accounting Officer
○○▼▼
Sarraf PashaDirector
○○
Garzone PamelaDirector
○○
Ahlers James MChief Financial Officer
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 3 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-12-30 · Sarraf Pasha.

Recent Form 4 activity

5Purchases
15Sales
15Other Form 4 lines
19SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING15 sale line(s) · context only
OTHER15 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
702,198
Previous report
332,105
Avg daily volume
666,076
Days to cover
1.1

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-12-30Sarraf PashaPurchase (P)Common Stock323,857USD 0.31USD 99,719SEC filing ↗
2024-12-16PASSERI DANIEL RPurchase (P)Common Stock30,000USD 1.03USD 30,900SEC filing ↗
2023-08-25Suri AnishPurchase (P)Common Stock4,000USD 2.76USD 11,040SEC filing ↗
2023-08-14PASSERI DANIEL RPurchase (P)Common Stock3,000USD 2.86USD 8,580SEC filing ↗
2022-05-27Morich FrankPurchase (P)Common Stock28,000USD 3.75USD 105,000SEC filing ↗
2022-05-24Fletcher Aaron G.L.Purchase (P)Common Stock55,000USD 3.34USD 183,700SEC filing ↗
2022-05-23Fletcher Aaron G.L.Purchase (P)Common Stock150,000USD 3.52USD 528,000SEC filing ↗
2022-03-31Fletcher Aaron G.L.Purchase (P)Common Stock735,000USD 4.76USD 3,498,600SEC filing ↗
2021-09-24PASSERI DANIEL RPurchase (P)Common Stock3,400USD 14.72USD 50,048SEC filing ↗
2021-01-20Pienta KennethPurchase (P)Common Stock2,720USD 15.07USD 40,990SEC filing ↗
2020-11-24Fletcher Aaron G.L.Purchase (P)Common Stock6,548USD 12.64USD 82,767SEC filing ↗
2020-09-30Gray CameronPurchase (P)Common Stock5,000USD 15.30USD 76,500SEC filing ↗
2020-09-29Gray CameronPurchase (P)Common Stock5,000USD 15.00USD 75,000SEC filing ↗
2020-06-24Fletcher Aaron G.L.Purchase (P)Common Stock7,500USD 24.88USD 186,572SEC filing ↗

Form 4 evidence

35 transaction lines in the latest 365-day window; 113 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-12Ray SumitaSale (S)Common Stock1,844USD 28.05USD 51,724SEC filing ↗
2026-10-12Meluzio Michael VincentSale (S)Common Stock1,144USD 28.05USD 32,089SEC filing ↗
2026-10-12Lin Shao-LeeSale (S)Common Stock11,087USD 27.55USD 305,490SEC filing ↗
Show recent Form 4 evidence (23 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-12Ray SumitaSale (S)Common Stock1,844USD 28.05USD 51,724SEC filing ↗
2026-10-12Meluzio Michael VincentSale (S)Common Stock1,144USD 28.05USD 32,089SEC filing ↗
2026-10-12Lin Shao-LeeSale (S)Common Stock11,087USD 27.55USD 305,490SEC filing ↗
2026-08-13Ray SumitaSale (S)Common Stock8,829USD 30.09USD 265,628SEC filing ↗
2026-08-13Ray SumitaOption exercise / conversion (M)Common Stock18,196USD 0.00USD 0SEC filing ↗
2026-08-13Meluzio Michael VincentSale (S)Common Stock5,628USD 30.09USD 169,324SEC filing ↗
2026-08-13Meluzio Michael VincentOption exercise / conversion (M)Common Stock13,647USD 0.00USD 0SEC filing ↗
2026-08-13Lin Shao-LeeSale (S)Common Stock18,258USD 28.62USD 522,573SEC filing ↗
2026-08-12Lin Shao-LeeSale (S)Common Stock40,000USD 27.10USD 1,083,989SEC filing ↗
2026-08-12Lin Shao-LeeOption exercise / conversion (M)Common Stock109,179USD 0.00USD 0SEC filing ↗
2026-07-30Ahlers James MAward / grant (A)Common Stock25,500USD 0.00USD 0SEC filing ↗
2026-07-13Borie Dominique ChristianAward / grant (A)Common Stock31,500USD 0.00USD 0SEC filing ↗
2026-07-09Sarraf PashaAward / grant (A)Common Stock18,400USD 0.00USD 0SEC filing ↗
2026-07-09Garzone PamelaAward / grant (A)Common Stock18,900USD 0.00USD 0SEC filing ↗
2026-07-09Sarraf PashaAward / grant (A)Common Stock21,800USD 0.00USD 0SEC filing ↗
2026-07-09Ray SumitaAward / grant (A)Common Stock54,589USD 0.00USD 0SEC filing ↗
2026-07-09Meluzio Michael VincentAward / grant (A)Common Stock40,942USD 0.00USD 0SEC filing ↗
2026-07-09Meehan Viola MongAward / grant (A)Common Stock21,800USD 0.00USD 0SEC filing ↗
2026-07-09Lin Shao-LeeAward / grant (A)Common Stock327,537USD 0.00USD 0SEC filing ↗
2026-07-09Garzone PamelaAward / grant (A)Common Stock21,800USD 0.00USD 0SEC filing ↗
2026-07-09Camardo Daniel A.Award / grant (A)Common Stock21,800USD 0.00USD 0SEC filing ↗
2026-05-03Lin Shao-LeeAward / grant (A)Common Stock327,537USD 0.00USD 0SEC filing ↗
2025-12-30Sarraf PashaPurchase (P)Common Stock323,857USD 0.31USD 99,719SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerCUE
CIK0001645460
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history113 transaction lines from 2020-03-31 to 2026-10-12
19 P purchase lines · 34 S sale lines · 60 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.